Secondary Logo

Share this article on:

Central Nervous System Aspergillosis: A Series of 14 Cases From a General Hospital and Review of 123 Cases From the Literature

Kourkoumpetis, Themistoklis K. MD; Desalermos, Athanasios MD; Muhammed, Maged MD; Mylonakis, Eleftherios MD, PhD

doi: 10.1097/MD.0b013e318274cd77
Original Study

Central nervous system (CNS) aspergillosis is a highly fatal infection. We review the clinical presentation, diagnosis, and outcome of this infection and present a case series of 14 consecutive patients with CNS aspergillosis admitted to Massachusetts General Hospital (MGH) from 2000 to 2011. We also review 123 cases reported in the literature during that time. We included only proven CNS aspergillosis cases conforming to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive fungal infections. In the MGH case series, neutropenia, hematologic malignancies, autoimmune diseases requiring steroid treatment, and solid organ transplantation were the predominant comorbid conditions. Notably, all MGH patients were immunosuppressed, and more than half (n = 8) had a history of previous brain injury, unrelated to their index hospitalization. For most MGH patients (11 of 14), the lung was the primary focus of aspergillosis, while 2 had paranasal sinus involvement, and 1 had primary Aspergillus discitis. Among reported cases, paranasal sinuses (27.6%) and the lung (26.8%) were the primary foci of infection, whereas 22% of those cases had no obvious primary organ involvement. Although a selection bias should be considered, especially among published cases, our findings suggest that patients who underwent neurosurgery had improved survival, with MGH and literature patients having 25% and 28.6% mortality, respectively, compared to 100% and 60.4%, respectively, among patients who received only medical treatment. Although this was not the case among MGH patients, CNS aspergillosis can affect patients without significant immune suppression, as indicated by the high number of reported immunocompetent cases. In conclusion, mortality among CNS aspergillosis patients remains high, and the infection may be more common among patients with previous brain pathology. When indicated, neurosurgical procedures may improve prognosis.

From the Department of Medicine, Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. (Dr. Mylonakis’ current affiliation is Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island.).

The Mylonakis laboratory has received research funding from Astellas Pharma, Inc. The funds were for research unrelated to the current work. For the remaining authors no conflicts of interest were declared.

Reprints: Eleftherios Mylonakis, MD, PhD, Chief, Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI 02912 (e-mail: emylonakis@lifespan.org).

Back to Top | Article Outline

INTRODUCTION

Central nervous system (CNS) aspergillosis is an often fatal infection that mainly involves immunosuppressed patients. The case-fatality ratio of patients with CNS aspergillosis is the highest of all forms of aspergillosis;50 mortality can be as high as 100%.61,81 Mortality in patients treated with voriconazole is still unacceptably high, and more efficacious treatments are needed. The rare clinical occurrence of CNS aspergillosis necessitates the presentation of case series and case reports of these patients. We conducted the current study to review the clinical presentation, diagnosis, and outcome of CNS aspergillosis over the last decade. We present 14 new cases of proven CNS aspergillosis that were treated at Massachusetts General Hospital (MGH) and report the clinical presentation and outcome of these patients. Also, we review all cases of confirmed CNS aspergillosis reported in the English-language literature from 2000 to 2011.

Back to Top | Article Outline

PATIENTS AND METHODS

We included 14 consecutive patients who developed CNS aspergillosis and were hospitalized at MGH from 2000 to 2011. We identified cases through 2 MGH-based databases: first, the MGH-Research Patient Data Registry, which identifies cases through their corresponding International Classification of Disease, 9th revision (ICD-9) codes for aspergillosis. Since there is no specific code for CNS aspergillosis, we manually reviewed all retrieved aspergillosis cases to identify those with CNS involvement. The second database we used was the MGH Microbiology Laboratory database.

Cases were not overlapping, and we included only patients with proven CNS aspergillosis according to the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) for deep tissue mold infections.5 These criteria divide patients into proven, probable, and possible cases according to symptoms, culture, and serologic criteria. To diagnose a proven deep tissue mold infection, EORTC/MSG criteria state that histopathologic or cytopathologic evidence of hyphae from needle aspiration or biopsy specimen with evidence of associated tissue damage (either microscopically or unequivocally by imaging) is needed; otherwise, a positive culture result for a sample obtained by sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with infection, excluding urine and mucous membranes, is sufficient.

We collected all patient characteristics through a retrospective review of electronic medical record files. Study variables included basic demographics and clinical and laboratory characteristics, such as underlying conditions, clinical signs and symptoms, and outcome. We gave special attention to therapeutic modalities such as surgical and antifungal treatment, as well as CNS imaging techniques including computed tomography (CT) and magnetic resonance imaging (MRI).

For the literature review, we searched PubMed (National Library of Medicine, Bethesda, MD) using the terms “brain” and/or “aspergillosis” and/or “Aspergillus” and/or “central nervous system.” We focused our search on papers published in English from 2000 to 2011 to reflect recent changes in clinical practice. Some of the cases included in this report were treated before 2000 but were presented on or after 2000. As noted above, only studies presenting proven CNS aspergilloses were included. All other probable or possible cases were excluded from the study. We defined neutropenia as <1500 neutrophils/μL, and corticosteroid (steroid) treatment as intake of >10 mg of prednisone equivalent per day. Initiation of an antifungal agent without any clinical signs of invasive fungal infection was considered prophylactic treatment. Antifungal treatment given in a symptomatic patient suspicious for invasive fungal infection without microbiologic confirmation was considered empiric treatment.

Back to Top | Article Outline

RESULTS

MGH Patients

Characteristics of MGH patients are summarized in Tables 1 and 2. The mean age of our patients was 56 years (range, 31–71 yr) with a slight female predominance (8 to 6, 57.1%). Most patients were white (n = 13), and 1 was Asian. The major comorbid condition was neutropenia (n = 6), with 3 of the cases attributable to hematologic malignancies. Other comorbid conditions included hematologic malignancies (n = 4), autoimmune diseases requiring steroid treatment (n = 4), diabetes mellitus (n = 3), transplantation (n = 3), hepatic insufficiency (n = 3), chronic obstructive pulmonary disease (1 of them on steroid therapy) (n = 2) and sarcoma (n = 1). It is notable that no bone marrow transplant recipients or patients with human immunodeficiency virus (HIV) were found to have proven CNS aspergillosis during that period. Some patients had more than 1 underlying clinical condition. Among the 3 diabetic patients, 1 was a solid organ transplant recipient, another had a hematologic malignancy, and the third had chronic renal failure.

TABLE 1

TABLE 1

TABLE 2

TABLE 2

We note that in 8 of 14 patients (57.1%), previous brain pathology was noted in their medical histories or in previous brain imaging. One patient had ischemic changes, 2 had brain infarctions, 2 had malignant metastases to the CNS, 1 had sign of microhemorrhages, and 2 had CNS infections, including 1 case of multiple Candida species with spinal cord involvement and 1 case with dystrophic brain calcifications of unknown etiology.

Most of the MGH patients with CNS aspergillosis had primary lung involvement with subsequent dissemination to the CNS. More specifically, 11 of 14 patients had primary pulmonary invasive aspergillosis (IA), 2 had primary paranasal sinus involvement, and 1 had primary spine aspergillosis. Two of the patients with primary lung aspergillosis had dissemination of IA to other organs in addition to the CNS. Both of these patients had simultaneous thyroid and gastrointestinal tract involvement; 1 also had metastasis of Aspergillus to the heart, and the other had metastases to the kidneys and paraspinal soft tissues.

Of the 2 patients with paranasal involvement, 1 was on corticoid treatment (daily prednisone 60 mg) for a presumed inflammatory process extending to the optic nerve. A biopsy of that lesion showed no evidence of infection, and after steroid treatment for the next 2 months the patient’s clinical situation deteriorated. A subsequent CNS biopsy done at that time confirmed the presence of Aspergillus hyphae. The other patient with primary paranasal aspergillosis had an extensive history of diabetes, chronic renal failure, prolonged total parenteral nutrition, and chronic pancreatitis. All other 11 patients with lung involvement had some history of immunosuppression, such as hematologic malignancies. Of note, most MGH patients were receiving either chronic steroids (71.4%) or cancer chemotherapy (21.4%) for underlying conditions, except 1 patient for whom medications and previous medical history at the time of admission were not available.

The clinical presentation of patients with CNS aspergillosis was variable and nonspecific. Fever was the predominant symptom, noted in 8 of 14 patients (57.1%). Other signs and symptoms included focal neurologic abnormalities in 5 patients (35.7%), seizures in 4 (28.6%), mental status changes in 3 (21.4%), and headaches in 2 patients (14.3%).

Cerebrospinal fluid (CSF) is rarely helpful for the diagnosis of CNS aspergillosis, although cases of Aspergillus meningitis with positive CSF culture have been reported.36 Notably, in 7 of the 14 MGH patients with a CSF culture, none was positive for Aspergillus. Regarding CSF chemical evaluation, glucose was high in 4 cases. In 2 cases, the CSF protein was 85 mg/dL and 235 mg/dL respectively, in 3 cases it was not measured, and in 2 cases it was in the reference range (15–60 mg/dL). White blood cell counts were elevated in 4 patients, although they were significantly variable (range, 6–530 cells/μL): 530 cells/μL, 200 cells/μL, 11 cells/μL, and 6 cells/μL, respectively. We identified differential CSF counts in only 2 patients who had, respectively, 91% and 98% neutrophil predominance.

Radiologic imaging is useful for diagnosing CNS aspergillosis; however, there were no unique characteristics that could differentiate an infection from other types of space-occupying lesions. Four MGH patients underwent CT scans, which revealed 1 ring-enhancing lesion, 2 brain hemorrhages (probably due to angioinvasion from Aspergillus), and 1 expanding lesion from the paranasal sinuses. Findings from MRI, which was performed in 9 patients, consisted of ring-enhancing lesions (n = 4), nonspecific hyperintense foci (n = 3) and expansion of infection from the paranasal sinuses (n = 2).

Regarding the infecting species of Aspergillus, 5 cases were associated with A. fumigatus, while in all other cases the causative microorganism was identified only to the genus level. Speciation of fungi such as Aspergillus is clinically important, since some species have been associated with higher antifungal resistance, such as A. terreus.87 Galactomannan, which is another important adjunct to the diagnosis of IA, was measured in only 2 patients. One patient had a positive galactomannan assay result of 0.79 ng/mL in the CSF, and the other patient had a result of 1.56 ng/mL (a value >0.5 ng/mL was considered positive).

Regarding antifungal strategies, we divided patients into 3 groups: patients who received antifungal therapy only, patients who received antifungal treatment and underwent neurosurgery, and patients who received no therapy (no patient underwent neurosurgery without receiving antifungal agents). The group with antifungal therapy only comprised 5 patients, all of whom subsequently died. One patient received prophylactic fluconazole and was subsequently treated with amphotericin B, 1 received amphotericin B, 1 received voriconazole as prophylaxis, 1 received fluconazole as prophylaxis and then switched to micafungin and then to voriconazole, and the fifth patient received empiric coverage with amphotericin B, which was switched to caspofungin, and then, when diagnosis was established, changed to voriconazole.

The second group comprised 8 patients who received antifungal treatment and underwent neurosurgery. The type of neurosurgery performed included left frontotemporal craniotomy and debridement of orbital roof and dural biopsies (1 patient), bifrontal craniotomy with intradural and extradural debridement with left orbital exenteration (1 patient), left orbital exenteration (1 patient), and a resection of an aspergilloma (1 patient) and abscess drainage (4 patients). In this group only 2 patients died (25% mortality). Of the 2 patients who died, 1 had primary lung aspergillosis and received empirical liposomal amphotericin B but died before the results of brain cultures were finalized. The second patient, who had primary paranasal sinus aspergillosis, received a triple combination of liposomal amphotericin B, voriconazole, and micafungin, and subsequently died.

The third group consisted of 1 patient who received no medical or surgical therapy and died (the diagnosis was established at autopsy).

Regarding contraindications in the 6 patients who did not have surgery, 2 patients did not have surgery because of end-stage liver disease. Another patient had myelodysplastic conversion to acute myeloid leukemia and pancytopenia, and we could not assess the reason for the last 3 patients. The mean number of days from the onset of symptoms to death was 9 days. Eight of 14 patients died during their initial hospitalization (57.1% mortality). For the 6 patients who were alive on discharge, we reviewed their medical records to determine their outcome. Two patients were alive after 2 years, and another 2 patients were alive at 2 and 3 months postdischarge, respectively, although no subsequent follow-up was available. One patient died after 4 years from hematologic malignancy. For 1 patient no follow-up was available.

Back to Top | Article Outline

Literature Review

We identified 123 published cases of proven CNS aspergillosis.1–4,6,7,9–12,14–20,24–26,28,29,31–38,40–49,51,52,54–56,58–71,73,75–79,83–86,88–92,94–101 Baseline characteristics are presented in Table 3.

TABLE 3

TABLE 3

The mean age of the patients was 42.6 years (range, 2 d to 78 yr), with a male predominance (56.1%). Patients had a wide spectrum of comorbidities, such as diabetes (17.9%), hematologic malignancies (11.4%), transplantation (8.9%), HIV (8.1%), autoimmune diseases requiring steroids (4.9%), hepatic insufficiency (3.2%), bone marrow transplantation (2.4%), and chronic obstructive pulmonary disease (0.8%). Some patients had more than 1 comorbidity, but 29 patients (23.6%) had no reported associated conditions.10,14,18,24,27,29,31,34,37,38,41,45,46,48,51,52,56,59,62,64,66,73,76,85,86,92 Six of 123 patients (4.9%) had a wide spectrum of brain/cranial pathology in their previous histories or imaging. The 4.9% rate is low compared to our finding in the MGH patients of 57.1%. Since to the best of our knowledge, no other study has identified this finding as a potential risk factor, it is reasonable to assume that it was not rigorously sought in the previously reported cases.

Potential sites of primary infection included paranasal sinuses (34 patients; 27.6%); lungs (33 patients; 26.8%); ear canal (3 patients; 2.4%); cranial bones from trauma or surgical contamination (3 patients; 2.4%); and aortic, cardiac, or vertebral disc involvement (1 patient each; 0.8%). It is noteworthy that 28 patients (22.8%) had primary CNS involvement with no obvious primary site.20,27–29,31,55,62,63,67,86,92 In 7 of the patients with primary CNS involvement, infection was associated with contamination of the epidural catheterization kit permitting direct seeding of the CNS.34,36,52,76 Twenty patients did not have an apparent primary site of infection. In addition to the CNS, 14 patients (11.4%) had metastasis of Aspergillus to distant sites. Organs most commonly involved were the kidneys (3.3%), heart (3.3%), thyroid (2.4%), liver (1.6%), and spleen (0.8%).

Imaging findings were not thoroughly presented in the literature, thus we omitted these data from our report and focused on the imaging data from our case series.

Regarding signs and symptoms, fever (>38°C) was noted in 43 patients (35%), while low-grade fever (37–38°C) was present in 3 patients (2.4%). Also, 51 patients (41.5%) experienced headaches, 30 (24.4%) had mental status changes, and 11 (8.9%) had generalized seizures. Thirty-five patients (28.5%) had some form of focal neurologic abnormality such as hemiplegia (n = 18), and/or cranial nerve palsy (n = 34), and/or vision changes (n = 21).

Of the 123 literature patients, 60 (48.8%) received some form of immunosuppressant medication: 27 (21.9%) were receiving steroids, 8 (6.5%) cancer chemotherapy, 6 (4.9%) cyclosporin, 5 (4.1%) antithymocyte globulin, 5 (4.1%) mycophenolate, 5 (4.1%) tacrolimus, 1 (0.8%) anti-tumor necrosis factor (TNF)-alpha, 1 (0.8%) cyclophosphamide, 1 (0.8%) leflunomide, and 1 (0.8%) methotrexate. Among patients with lung involvement, 26 of 33 (78.8%) had some form of immunosuppression such as HIV infection, hematologic malignancy, or inherited immune deficiency. On the other hand, among 34 patients with paranasal sinus aspergillosis, 13 had an unknown immune status, and of the remaining 21 cases, 15 (71.5%) were immunosuppressed.

A. fumigatus was the predominant species causing infection in 41 patients (33.3%), with A. flavus, A. versicolor, and A. granulosus causing infections in 7, 1, and 1 patient, respectively. In 29 patients, Aspergillus was identified only to the genus level (23.6%). Galactomannan serologic levels were reported in 8 cases (reference range, <0.5 ng/mL). Levels were 1.3 ng/mL in 1 patient, 5.44–9.4 ng/mL in another patient, and 1.9–5 ng/mL, 1.3 ng/mL, and 0.475 ng/mL for 3 other patients, respectively. One additional result was reported as “negative,” and 2 results were reported as “positive” without any detailed values.

The choice of antifungal treatment reported in the literature is summarized in Table 4. Only a minority of patients received prophylactic treatment (n = 7), including fluconazole (n = 4), itraconazole (n = 2), and amphotericin B (n = 1); or empiric antifungal treatment (n = 6), including amphotericin B (n = 3), voriconazole (n = 2), and fluconazole (n = 1). Also, only 24.4% of patients received voriconazole, and 55.3% received amphotericin B, 20.3% received itraconazole, 9.8% caspofungin, 5.7% fluconazole, 4% micafungin, 2.4% 5-flucytosine, and 0.8% terbinafine. Regarding combination therapy, amphotericin was administered with the following: itraconazole (10 cases), voriconazole (4 cases), 5-flucytosine (3 cases), fluconazole (3 cases), caspofungin (3 cases), and voriconazole along with caspofungin (3 cases). Two patients received voriconazole with caspofungin. All 16 patients who did not receive antifungal treatment subsequently died, and treatment data were not available for 11 patients. Overall, 53 patients survived, 64 died, and the outcome was not reported for 6 patients. Mortality with amphotericin monotherapy was 62.5% (15 of 24) and with voriconazole monotherapy it was 35.4% (4 of 11). One patient who died in the voriconazole monotherapy group discontinued maintenance voriconazole therapy at 6 weeks against medical advice and had symptom recurrence and rapid deterioration in the hospital.

TABLE 4

TABLE 4

As in the MGH patient group, neurosurgical procedures were performed in a significant number of the cases from the literature (n = 49). Eighteen patients underwent abscess removal or drainage, 18 had excision of infected mass, 4 orbital exenterations, 1 debridement of inner ear, and 1 debridement of the skull base; 7 patients underwent neurosurgery but the type of operation was not mentioned. Of the 49 patients who underwent a neurosurgical procedure, 6 had an unknown outcome (12.2%) and 14 patients died (28.6%). Of the 74 patients who did not undergo neurosurgery, 50 died (67.5%). Of the 74 patients who did not undergo neurosurgical procedure, 54 received antifungal treatment, and 60.4% of them died during hospitalization. (Due to insufficient data, we cannot report the reasons for not performing neurosurgery among patients from the literature.)

Back to Top | Article Outline

DISCUSSION

We present 14 patients with CNS aspergillosis who were treated at MGH from 2000 to 2011. We also review 123 cases reported in the literature during the same period. Hematologic malignancies and concomitant neutropenia were the major underlying diseases; the most common primary sites of aspergillosis were the lungs and the paranasal sinuses. Neutropenia and steroid therapy were the most common predisposing factors. In the MGH series, a significant number of patients had a history of previous brain pathology, which could predispose them to metastasis of infection to the CNS, presumably due to a disruption of the blood brain barrier. We note that a significant number of patients with CNS aspergillosis reported in the literature had no apparent immune suppression, while diabetes was associated with a significant number of paranasal aspergillosis cases. Mortality was high even among patients who received voriconazole, and, as discussed below, our findings suggest that patients who underwent neurosurgery had better survival than those who received only medical therapy, although this could reflect a selection bias.

Neutropenia was the major underlying condition in the MGH series: it complicated 6 of 14 patients. Unfortunately, neutrophil counts were not widely reported in the literature (for example, 52 published cases did not report white blood cell counts), thus we reported results only from our series. Neutrophils have a major contribution in the extracellular killing of Aspergillus hyphae.22 The immune system has the ability to clear conidia by employing macrophages that phagocytose and then kill them. Complement is another form of defense, and has the ability to bind to swollen conidia and hyphae.8 Neutrophils are recruited by macrophages and release reactive oxygen species and other proteolytic substances. In the setting of neutropenia or dysfunctional neutrophils, such as in chronic granulomatous disease, the risk of IA is increased and the risk for subsequent metastasis of Aspergillus to other organs such as the CNS is high. Steroids have traditionally been shown to increase the risk for aspergillosis; the proposed mechanism involves their immunosuppressant effect on immune cells and also their presumed direct trophic effect on Aspergillus.22

In the MGH series, 8 of 14 patients had some previous form of brain pathology. This finding could underline a possible mechanism of invasion. For example, an abnormal blood brain barrier, such as in areas of glial scars, could possibly aid the attachment and subsequent invasion of Aspergillus in the CNS. A larger comparative study could perhaps lead to better conclusions; however, a previous history of brain damage or proof of older imaging abnormalities in immunocompromised patients should alert the physician to the risk of subsequent CNS aspergillosis.

Our results indicate that even though IA is more common among individuals with a compromised immune system, it can also infect patients with no obvious immune suppression. All 14 MGH patients had some form of immunosuppression; however, 29 of 123 literature patients had no underlying immunocompromising disease, such as hematologic malignancy, cancer, or HIV infection.10,18,24,29,34,46,52,56,59,64,74,76,85,86,92 Recent experimental research in this field has shown that certain immune receptor deficiencies may predispose to aspergillosis despite what appears to be a normal immune system. We assume that this phenomenon could be explained by defects in toll-like receptors13 or defects in dectin-1, which is able to recognize β-glucan,30,57 a component of numerous fungal cell wall species like Aspergillus. Presumably in the latter case, the host may have normal quantitative and qualitative aspects of the immune system, but inherent defects in pattern recognition molecules like dectin-1 may cause increased susceptibility to invasive fungal infections.

A noteworthy finding in the current study is the high prevalence of diabetes mellitus in both the MGH and the literature patients. Fourteen of the 22 diabetic patients from the literature had primary diabetes mellitus with no other comorbidities, whereas all 3 MGH patients with diabetes mellitus had other comorbidities, such as chronic renal failure, transplantation, or hematologic malignancy. Diabetes is known to have an immunosuppressive effect, but the association between diabetes mellitus and IA has not been studied extensively. We can assume that depressed phagocyte activity induced by diabetes might aid in the increased survival of Aspergillus in mucosal surfaces through a decrease in fungal mucosal clearance.39 Diabetes mellitus has been associated with other forms of fungal sinusitis, including mucormycosis.

Unfortunately, the differential diagnosis of CNS aspergillosis can be broad, and clinical symptoms are not a sensitive diagnostic tool. For example, in the current MGH series only about half (8/14; 57.1%) of patients had fever, and focal neurologic abnormalities were evident in about 36% of patients (n= 5). Seizures, mental status deterioration, and headaches were reported in 29%, 21%, and 14% of the 14 patients in the MGH series, respectively. These numbers coincided with results from the literature, where 42% of patients had headaches, 37% had fever, 29% focal neurologic abnormalities, 24% mental status changes, and 9% seizures. More specific assays are needed to diagnose IA; rapid diagnostic polymerase chain reaction (PCR) techniques performed in the CSF and serum could facilitate a faster and simpler diagnostic approach in the future.40

Since its approval by the United States Food and Drug Administration (FDA), voriconazole has become the standard of care in most cases of IA. In treating CNS aspergillosis, voriconazole can achieve CSF levels that are above its minimum inhibitory concentration.21,72,82 Although low voriconazole levels have been linked to clinical failure,93 they were scarcely reported in our review. Clinicians treating patients with CNS aspergillosis should monitor serum voriconazole levels, usually starting 5 days after the initiation of therapy.93 Voriconazole levels in the CSF can range widely, and the therapeutic CSF levels have not been established. For example, in a small study that evaluated the pharmacokinetics of voriconazole, 1 patient with CSF levels of 2.41 μg/mL 2 hours after the first oral dose of voriconazole (6.3 mg/kg) had partial response to therapy, whereas another patient on voriconazole dose 4 mg/kg had a significantly lower level (0.23 μg/mL) and did not respond to treatment.53 Additional studies should evaluate the clinical significance of CSF levels in the management of CNS aspergillosis. Voriconazole levels were not measured during the hospitalization of MGH patients, and in the literature they were scarcely reported.

Of special interest is that not all of our patients received voriconazole, even though it is the single most important antifungal agent used in CNS aspergillosis.80 Voriconazole was used in only 8 of 14 MGH patients. Although during the first 5 years of our review this could be partially explained by a delay in clinical acceptance, even during the last 5 years voriconazole was used in only about half of our patients. The reasons for this are unclear. A potential explanation could be the delay in diagnosis that prompts clinicians to use empiric amphotericin B, which provides broader antifungal coverage until definitive diagnosis. Also, clinicians might feel uncomfortable using voriconazole due to the lack of data on the appropriate therapeutic levels for the management of CNS aspergillosis. Thus, until definitive diagnosis, patients are often exposed to suboptimal antifungal coverage.

Neurosurgery had a favorable outcome for both MGH and literature patients. All MGH patients who survived had some type of neurosurgery, and among literature patients, neurosurgery had a favorable outcome. More specifically, mortality among MGH and literature patients was 25% and 28.6%, respectively, compared to 100% and 60.4%, respectively, among patients who received only medical treatment. This underlines the importance of surgical intervention in the management of CNS aspergillosis; however, there is also the possibility that patients who underwent surgery were in better clinical condition. The good rates of survival with neurosurgery reported in the literature might also be biased, because it is more common for significant results to be published.23 Until more efficacious treatment becomes available, the combination of effective antifungal therapy with neurosurgery should be strongly considered.

Back to Top | Article Outline

Conclusion

CNS aspergillosis usually involves immunocompromised patients; however, immunocompetent patients and those with “mild” immunosuppression, such as diabetes mellitus, may also be affected. CNS involvement often results from dissemination of the infection from the lungs and paranasal sinuses. A history of prior brain pathology in an immunocompromised patient with IA could be associated with a higher risk of CNS dissemination. The combination of antifungal therapy with neurosurgery appears to be the most promising approach. However, mortality is still unacceptably high, and more efficacious therapeutic approaches are needed. Although the rarity of CSF aspergillosis precludes conducting randomized controlled trials, large prospective cohorts can significantly help improve the outcome in these patients.

Back to Top | Article Outline

Abbreviations

CNS: central nervous system

CSF: cerebrospinal fluid

CT: computed tomography

EORTC/MSG: European Organization for Research and Treatment of Cancer/Mycoses Study Group

HIV: human immunodeficiency virus

IA: invasive aspergillosis

MGH: Massachusetts General Hospital

MRI: magnetic resonance imaging

TNF: tumor necrosis factor

Back to Top | Article Outline

REFERENCES

1. Abenza-Abildua MJ, Fuentes-Gimeno B, Morales-Bastos C, Aguilar-Amat MJ, Martinez-Sanchez P, Diez-Tejedor E. Stroke due to septic embolism resulting from Aspergillus aortitis in an immunocompetent patient. J Neurol Sci. 2009; 284: 209–210.
2. Alapatt JP, Kutty RK, Gopi PP, Challissery J. Middle and posterior fossa aspergilloma. Surg Neurol. 2006; 66: 75–78.
3. Alfano C, Chiummariello S, Dessy LA, Bistoni G, Scuderi N. Combined mucormycosis and aspergillosis of the rhinocerebral region. In Vivo. 2006; 20: 311–315.
4. Ardalan MR, Ansarin K, Hejazi E, Nazemieh M, Safa J. Aspergillosis after renal transplantation. Saudi J Kidney Dis Transpl. 2005; 16: 330–333.
5. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 7–14.
6. Azarpira N, Esfandiari M, Bagheri MH, Rakei S, Salari S. Cerebral aspergillosis presenting as a mass lesion. Braz J Infect Dis. 2008; 12: 349–351.
7. Balasubramaniam P, Madakira PB, Ninan A, Swaminathan A. Response of central nervous system aspergillosis to voriconazole. Neurol India. 2007; 55: 301–303.
8. Behnsen J, Hartmann A, Schmaler J, Gehrke A, Brakhage AA, Zipfel PF. The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun. 2008; 76: 820–827.
9. Binder C, Ruchel R. Case report. Mixed systemic mycosis with fatal outcome in a patient with acute myeloblastic leukaemia. Mycoses. 2000; 43: 59–63.
10. Brun S, Fekkar A, Busse A, Seilhean D, Lecso M, Adler D, Prodanovic H, Mazier D, Datry A. Aspergillus flavus brain abscesses associated with hepatic amebiasis in a non-neutropenic man in Senegal. Am J Trop Med Hyg. 2009; 81: 583–586.
11. Buxhofer V, Ruckser R, Kier P, Habertheuer KH, Tatzreiter G, Zelenka P, Dorner S, Sebesta C, Knosp E, Hruby W, Hinterberger W. Successful treatment of invasive mould infection affecting lung and brain in an adult suffering from acute leukaemia. Eur J Haematol. 2001; 67: 128–132.
12. Castro S, Bartosch C, Seixas D, Ayres Basto M, Exposito M, Carpenter S, Bernardes I. Granulomatous infectious disease in an immunosuppressed patient: a case report with radiological and pathological correlation. J Neuroradiol. 2009; 36: 165–169.
13. Chignard M, Balloy V, Sallenave JM, Si-Tahar M. Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromized hosts. Clin Immunol. 2007; 124: 238–243.
14. Cho YS, Lee DK, Hong SD, Oh WS. Intracranial aspergillosis involving the internal auditory canal and inner ear in an immunocompetent patient. AJNR Am J Neuroradiol. 2007; 28: 138–140.
15. Choi MY, Bae IH, Lee JH, Lee SJ. Aspergillosis presenting as an optic neuritis. Korean J Ophthalmol. 2002; 16: 119–123.
16. Coates M, Wilson J. Central nervous system Aspergillus infection complicating renal transplantation. Australas Radiol. 2001; 45: 338–342.
17. Colombo AL, Rosas RC. Successful treatment of an Aspergillus brain abscess with caspofungin: case report of a diabetic patient intolerant of amphotericin B. Eur J Clin Microbiol Infect Dis. 2003; 22: 575–576.
18. Curone M, D’Amico D, Maccagnano E, Bussone G. Fatal Aspergillus brain abscess in immunocompetent patient. Neurol Sci. 2009; 30: 233–235.
19. Damek DM, Lillehei KO, Kleinschmidt-DeMasters BK. Aspergillus terreus brain abscess mimicking tumor progression in a patient with treated glioblastoma multiforme. Clin Neuropathol. 2008; 27: 400–407.
20. de Lastours V, Lefort A, Zappa M, Dufour V, Belmatoug N, Fantin B. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis. 2003; 22: 297–299.
21. Denes E, Pichon N, Debette-Gratien M, Bouteille B, Gaulier JM. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin Infect Dis. 2004; 39: 603–604.
22. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781–803.
23. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991; 337: 867–872.
24. Elgamal EA, Murshid WR. Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literature. Br J Neurosurg. 2000; 14: 137–141.
25. Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol. 2002; 51: 70–75.
26. Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fatkenheuer G, Cornely OA. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents. 2006; 28: 262–265.
27. Endo T, Tominaga T, Konno H, Yoshimoto T. Fatal subarachnoid hemorrhage, with brainstem and cerebellar infarction, caused by Aspergillus infection after cerebral aneurysm surgery: case report. Neurosurgery. 2002; 50: 1147–1150; discussion 50-1.
28. Erdogan E, Beyzadeoglu M, Arpaci F, Celasun B. Cerebellar aspergillosis: case report and literature review. Neurosurgery. 2002; 50: 874–876.
29. Fernandes YB, Ramina R, Borges G, Queiroz LS, Maldaun MV, Maciel JA Jr. Orbital apex syndrome due to aspergillosis: case report. Arq Neuropsiquiatr. 2001; 59 (3-B): 806–808.
30. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morre SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, Netea MG. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009; 361: 1760–1767.
31. Figueiredo EG, Fonoff E, Gomes M, Macedo E, Marino Junior R. Tumoral form of aspergillosis in central nervous system (cerebral aspergilloma): case report. Sao Paulo Med J. 2003; 121: 251–253.
32. Florescu DF, Iwen PC, Hill LA, Dumitru I, Quader MA, Kalil AC, Freifeld AG. Cerebral aspergillosis caused by Aspergillus ustus following orthotopic heart transplantation: case report and review of the literature. Clin Transplant. 2009; 23: 116–120.
33. Garcia-Asensio S, Artigas JM, Barrena R. Optic nerve aspergillosis: report of a case diagnosed by fine-needle aspiration biopsy. Eur Radiol. 2000; 10: 573–575.
34. Genzen JR, Kenney B. Central nervous system Aspergillus infection after epidural analgesia: diagnosis, therapeutic challenges, and literature review. Diagn Microbiol Infect Dis. 2009; 65: 312–318.
35. Gubler C, Wildi SM, Imhof A, Schneemann M, Mullhaupt B. Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole. Infection. 2007; 35: 364–366.
36. Gunaratne PS, Wijeyaratne CN, Seneviratne HR. Aspergillus meningitis in Sri Lanka—a post-tsunami effect? N Engl J Med. 2007; 356: 754–756.
37. Hao L, Jing C, Bowen C, Min H, Chao Y. Aspergillus sellar abscess: case report and review of the literature. Neurol India. 2008; 56: 186–188.
38. Hiraga A, Uzawa A, Shibuya M, Numata T, Sunami S, Kamitsukasa I. Neuroaspergillosis in an immunocompetent patient successfully treated with voriconazole and a corticosteroid. Intern Med. 2009; 48: 1225–1229.
39. Hodgson KA, Morris JL, Feterl ML, Govan BL, Ketheesan N. Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect. 2011; 13: 1177–1184.
40. Hummel M, Spiess B, Kentouche K, Niggemann S, Bohm C, Reuter S, Kiehl M, Morz H, Hehlmann R, Buchheidt D. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol. 2006; 44: 3989–3993.
41. Iplikcioglu AC, Bek S, Bikmaz K, Ceylan D, Gokduman CA. Aspergillus pituitary abscess. Acta Neurochir (Wien). 2004; 146: 521–524.
42. Isaacs R, Calton N, Chopra R. Mycotic infections of brain. Indian J Pathol Microbiol. 2001; 44: 467–469.
43. Kaffarnik M, Utzolino S, Blaich A, Hopt UT. Successful multimodal therapy of invasive pulmonary and central nervous system aspergillosis in a neutropenic surgical patient: case report and review of the literature. Mycoses. 2008; 51: 74–78.
44. Khan ZU, Ahmad S, Mokaddas E, Said T, Nair MP, Halim MA, Nampoory MR, McGinnis MR. Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1→3)-beta-D-glucan in clinical specimens. J Med Microbiol. 2007; 56 (Pt 1): 129–132.
45. Kolbe AB, McKinney AM, Kendi AT, Misselt D. Aspergillus meningitis and discitis from low-back procedures in an immunocompetent patient. Acta Radiol. 2007; 48: 687–689.
46. Kose S, Cavdar G, Senger SS, Akkoclu G. Central nervous system aspergillosis in an immunocompetent patient. J Infect Dev Ctries. 2011; 5: 313–315.
47. Kroot EJ, Demeyere T, van der Linden AN, Visser C, Traksel RA. Intracranial aspergilloma in a patient with rheumatoid arthritis. Scand J Rheumatol. 2008; 37: 233–234.
48. Kulkarni V, Rajshekhar V, Mathews MS. An isolated non-dural-based cerebellar aspergilloma in an immunocompetent patient. Neurol India. 2007; 55: 310–311.
49. Lacerda JF, Martins C, Carmo JA, Lourenco F, Guedes MM, Sequeira P, Lacerda JM. Invasive aspergillosis of the central nervous system after allogeneic stem cell transplantation. J Infect. 2005; 51: e191–e194.
50. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001; 32: 358–366.
51. Liu W, Chen H, Cai B, Li G, You C, Li H. Successful treatment of sellar Aspergillus abscess. J Clin Neurosci. 2010; 17: 1587–1589.
52. Lokuhetty MD, Wijesinghe HD, Weerasundera B, Dayapala A. Iatrogenic Aspergillus infection of the central nervous system in a pregnant woman. Indian J Pathol Microbiol. 2009; 52: 427–429.
53. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003; 37: 728–732.
54. Marcinkowski M, Bauer K, Stoltenburg-Didinger G, Vogel M, Versmold H. Fatal aspergillosis with brain abscesses in a neonate with DiGeorge syndrome. Pediatr Infect Dis J. 2000; 19: 1214–1216.
55. Mardari R, Puppa AD, Rotilio A, Sgarabotto D, Baracchini C, Carollo C, Manara R. Pontocerebellar angle aspergillosis: clinical and radiological findings. Neurologist. 2011; 17: 75–78.
56. Marinovic T, Skrlin J, Vilendecic M, Rotim K, Grahovac G. Multiple Aspergillus brain abscesses in immuno-competent patient with severe cranio-facial trauma. Acta Neurochir (Wien). 2007; 149: 629–632.
57. Marodi L, Erdos M. Dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2010; 362: 367.
58. Martinez R, Castro G, Machado AA, Moya MJ. Primary aspergilloma and subacute invasive aspergillosis in two AIDS patients. Rev Inst Med Trop Sao Paulo. 2009; 51: 49–52.
59. Merseburger AS, Oelke M, Hartmann J, Stenzl A, Kuczyk MA. Intracranial aspergillosis in a non-immunocompromised patient treated for muscle-invasive bladder cancer. Int J Urol. 2004; 11: 666–668.
60. Mueller NJ, Weisser M, Fehr T, Wuthrich RP, Mullhaupt B, Lehmann R, Imhof A, Aubert JD, Genoni M, Kunz R, Weber M, Steiger J. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis. 2010; 12: 54–59.
61. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore). 2000; 79: 269–280.
62. Nabika S, Kiya K, Satoh H, Mizoue T, Araki H, Oshita J. Local administration of amphotericin B against aspergilloma in the prepontine cistern—case report. Neurol Med Chir (Tokyo). 2007; 47: 89–92.
63. Naidech A. A young woman with ring-enhancing lesions. J La State Med Soc. 2003; 155: 158–161.
64. Narayan SK, Kumar K, Swaminathan RP, Roopeshkumar VR, Bhavna B. Isolated cerebral aspergilloma in a young immunocompetent patient. Pract Neurol. 2009; 9: 166–168.
65. Norlinah MI, Ngow HA, Hamidon BB. Angioinvasive cerebral aspergillosis presenting as acute ischaemic stroke in a patient with diabetes mellitus. Singapore Med J. 2007; 48: e1–e4.
66. Notani K, Satoh C, Hashimoto I, Makino S, Kitada H, Fukuda H. Intracranial Aspergillus infection from the paranasal sinus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89: 9–11.
67. Okugawa S, Ota Y, Tatsuno K, Tsukada K, Kishino S, Koike K. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis. 2007; 39: 344–346.
68. Pagliano P, Attanasio V, Fusco U, Rossi M, Scarano F, Faella FS. Pulmonary aspergillosis with possible cerebral involvement in a previously healthy pregnant woman. J Chemother. 2004; 16: 604–607.
69. Palanisamy A, Chao SD, Fouts M, Kerr D. Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole. Am J Hosp Palliat Care. 2005; 22: 139–144.
70. Patiroglu T, Unal E, Yikilmaz A, Koker MY, Ozturk MK. Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located Aspergillus abscess mimicking intracranial tumor. Childs Nerv Syst. 2010; 26: 149–154.
71. Pellacchia V, Terenzi V, Moricca LM, Buonaccorsi S, Indrizzi E, Fini G. Brain abscess by mycotic and bacterial infection in a diabetic patient: clinical report and review of literature. J Craniofac Surg. 2006; 17: 578–584.
72. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol. 2009; 47: 3142–3146.
73. Pongbhaesaj P, Dejthevaporn C, Tunlayadechanont S, Witoonpanich R, Sungkanuparph S, Vibhagool A. Aspergillosis of the central nervous system: a catastrophic opportunistic infection. Southeast Asian J Trop Med Public Health. 2004; 35: 119–125.
74. Pushker N, Meel R, Kashyap S, Bajaj MS, Sen S. Invasive aspergillosis of orbit in immunocompetent patients: treatment and outcome. Ophthalmology. 2011; 118: 1886–1891.
75. Raparia K, Powell SZ, Cernoch P, Takei H. Cerebral mycosis: 7-year retrospective series in a tertiary center. Neuropathology. 2010; 30: 218–223.
76. Rodrigo N, Perera KN, Ranwala R, Jayasinghe S, Warnakulasuriya A, Hapuarachchi S. Aspergillus meningitis following spinal anaesthesia for caesarean section in Colombo, Sri Lanka. Int J Obstet Anesth. 2007; 16: 256–260.
77. Rossouw I, Goedhals D, van der Merwe J, Stallenberg VB, Govender NP. A rare, fatal case of invasive spinal aspergillosis in an antiretroviral-naive, HIV-infected man with pre-existing lung colonization. J Med Microbiol. 2011; 60: 1534–1538.
78. Rueter F, Hirsch HH, Kunz F, Buser P, Habicht JM, Moch H, Fluckiger U, Zerkowski HR. Late Aspergillus fumigatus endomyocarditis with brain abscess as a lethal complication after heart transplantation. J Heart Lung Transplant. 2002; 21: 1242–1245.
79. Saulsbury FT. Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis. 2001; 32: E137–E139.
80. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005; 106: 2641–2645.
81. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses. 2007; 50: 196–200.
82. Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med Mycol. 2009; 47 (Suppl 1): S387–S393.
83. Seton M, Pless M, Fishman JA, Caruso PA, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 18-2008. A 68-year-old man with headache and visual changes after liver transplantation. N Engl J Med. 2008; 358: 2619–2628.
84. Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery. 2004; 55: 602–611.
85. Siddiqui K, Douglas M, Carey M, Benamer H. A case of invasive aspergillosis in a patient with no identifiable immunodeficiencies. Libyan J Med. 2008; 3: 49–51.
86. Sood S, Sharma R, Gupta S, Pathak D, Rishi S. Neuroaspergillosis in an immunocompetent patient. Indian J Med Microbiol. 2007; 25: 67–69.
87. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B. resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999; 37: 2343–2345.
88. Sutton DA, Wickes BL, Romanelli AM, Rinaldi MG, Thompson EH, Fothergill AW, Dishop MK, Elidemir O, Mallory GB, Moonnamakal SP, Adesina AM, Schecter MG. Cerebral aspergillosis caused by Aspergillus granulosus. J Clin Microbiol. 2009; 47: 3386–3390.
89. Takahashi H, Hinohira Y, Hato N, Wakisaka H, Hyodo J, Ugumori T, Gyo K. Clinical features and outcomes of four patients with invasive fungal sinusitis. Auris Nasus Larynx. 2011; 38: 289–294.
90. Tattevin P, Bruneel F, Lellouche F, de Broucker T, Chevret S, Wolff M, Regnier B. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect. 2004; 10: 928–931.
91. Tendolkar U, Sharma A, Mathur M, Ranadive N, Sachdev M. Epidural mass due to Aspergillus flavus causing spinal cord compression—a case report and brief update. Indian J Med Microbiol. 2005; 23: 200–203.
92. Traboulsi RS, Kattar MM, Dbouni O, Araj GF, Kanj SS. Fatal brain infection caused by Aspergillus glaucus in an immunocompetent patient identified by sequencing of the ribosomal 18S-28S internal transcribed spacer. Eur J Clin Microbiol Infect Dis. 2007; 26: 747–750.
93. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007; 109: 1532–1535.
94. Tsai HC, Lee SS, Wann SR, Chen YS, Wang JS, Liu YC. Invasive pulmonary aspergillosis with cerebral abscess in a patient with idiopathic thrombocytopenic purpura. J Chin Med Assoc. 2006; 69: 278–281.
95. Tsitsopoulos PP, Tsoulfas G, Tsonidis C, Imvrios G, Papanikolaou V, Giakoustidis D, Marinopoulos D, Takoudas D, Tsitsopoulos PD. Successful, combined long-term treatment of cerebral aspergillosis in a liver transplant patient. Virulence. 2010; 1: 465–467.
96. Turgut M, Ozsunar Y, Oncu S, Akyuz O, Ertugrul MB, Tekin C, Gultekin B, Sakarya S. Invasive fungal granuloma of the brain caused by Aspergillus fumigatus: a case report and review of the literature. Surg Neurol. 2008; 69: 169–174.
97. Uppin MS, Challa S, Uppin SG, Alladi S, Yarlagadda JR. Cerebral Aspergillus arteritis with bland infarcts: a report of two patients with poor outcome. Neurol India. 2007; 55: 298–300.
98. Vener C, Carrabba M, Fracchiolla NS, Costa A, Fabio G, Hu C, Sina C, Guastella C, Pignataro L, Deliliers GL. Invasive fungal sinusitis: an effective combined treatment in five haematological patients. Leuk Lymphoma. 2007; 48: 1577–1586.
99. Vidal JE, Dauar RF, Melhem MS, Szeszs W, Pukinskas SR, Coelho JF, Lins DL, Costa SF, Penalva de Oliveira AC, Lacaz C. Cerebral aspergillosis due to Aspergillus fumigatus in AIDS patient: first culture-proven case reported in Brazil. Rev Inst Med Trop Sao Paulo. 2005; 47: 161–165.
100. Xie L, Gebre W, Szabo K, Lin JH. Cardiac aspergillosis in patients with acquired immunodeficiency syndrome: a case report and review of the literature. Arch Pathol Lab Med. 2005; 129: 511–515.
101. Zwitserloot AM, Warris A, van’t Hek LG, van Die LE, Verweij PE, Mavinkurve-Groothuis AM. Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008; 51: 423–426.
© 2012 Lippincott Williams & Wilkins, Inc.